NRX Pharmaceuticals Inc

NASDAQ:NRXP   1:00:00 PM EDT
1.15
+0.06 (+5.50%)
: $1.20 +0.05 (+4.35%)
Earnings Announcements

Nrx Pharmaceuticals Reports Q3 2022 Financial Results

Published: 11/14/2022 12:06 GMT
NRX Pharmaceuticals Inc (NRXP) - Nrx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update.
Qtrly Loss per Share $0.14.
Nrx Pharma - Plans to Initiate Phase 3 Trial of Nrx-101 in Patients With Bipolar Depression With Acute Suicidal Ideation and Behavior by Year-end.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.15

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.14

More details on our Analysts Page.